CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc., announced on September 18, 2025, that its Houston lab received a certificate of accreditation from the Centers for Medicare & Medicaid Services (CMS). This accreditation confirms compliance with Clinical Laboratory Improvement Amendments (CLIA) regulations.
This certification is a key milestone for the broad U.S. market release of the CNSide cerebrospinal fluid (CSF) assay platform. It underscores the company's commitment to the highest quality standards for testing human specimens.
Achieving CLIA compliance is necessary for several additional milestones, including securing reimbursement codes, negotiating payer agreements, and expanding commercial availability. This accreditation is a tangible accomplishment in the company's U.S. market access and launch strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.